DIVISLAB Divi's Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Divi's Laboratories reported a strong Q2 FY26, with consolidated total income growing 17% YoY to ₹2,860 crores and PAT increasing 35.1% to ₹689 crores. The custom synthesis segment was a key growth driver, contributing 56% to the product mix, while the generics business continued to face pricing pressures. The company is actively investing in capacity expansion, with H1 FY26 capex at ₹1,550 crores and full-year capex expected to exceed ₹2,000 crores, focusing on new projects, peptide synthesis, and Unit 3 operations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 15.6%, net profit up 34.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,302 | 2,297 | 2,536 | 2,357 | 2,660 +16% |
| EBITDA | 729 | 747 | 881 | 743 | 895 +23% |
| Net profit | 518 | 594 | 667 | 557 | 696 +34% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
